Alzheimer’s Studies and Trials

Filters
Filters
Enrollment Status
Study Type
Age Range
Cognitive Status
Show (8)
Cancel
Reset Filters
Actively Enrolling
, ,

AlzMatch Study

The AlzMatch Study tests whether a single blood test, collected at community-based laboratories, can help speed clinical trial enrollment by identifying people most likely to have amyloid in the brain.  Brain amyloid is a protein that builds up in people who may go on to have memory problems because of Alzheimer’s disease.  Many studies are looking for individuals who have an increased likelihood of having amyloid, and the AlzMatch Study seeks to simplify the screening process for these studies using a blood test.  AlzMatch is inviting participants who are registered in the Alzheimer Prevention Trials (APT) Webstudy and are over 50 years of age, with no diagnosis of dementia. After consent, the primary measures are engagement of eligible participants and collection of blood samples. All participants will be informed of their eligibility to be screened for a clinical study. If eligible and agree to referral, participants will be connected to a local research site for in-person evaluation.  Learn more about the APT Webstudy at: aptwebstudy.org   
Learn More
Actively Enrolling
, ,

Trial-Ready Cohort- Down Syndrome (TRC-DS)

The Trial-Ready Cohort- Down Syndrome (TRC-DS) aims to enroll 120 non-demented adults (ages 25-55) with Down syndrome (DS) into a trial ready cohort (TRC). Participants enrolled in the TRC-DS will undergo longitudinal cognitive and clinical assessment, genetic and biomarker testing, as well as imaging and biospecimen collection. Using these outcome measures, researchers will analyze the relationships between cognitive measures and biomarkers of Alzheimer’s disease (AD) to identify endpoints for AD clinical trials in DS that best reflect disease progression.
Learn More
Actively Enrolling
, , ,

Longitudinal Early-Onset Alzheimer’s Disease Study (LEADS)

The LEADS study – or the Longitudinal Early-Onset Alzheimer’s Disease Study (LEADS) explores the development of early-onset Alzheimer’s disease and how it compares to the more common late-onset Alzheimer’s disease. Better understanding of this form of the disease may ultimately lead to more effective treatments. LEADS is a 2-year observational study designed to enroll 500 participants. Researchers are also recruiting cognitively normal volunteers for a 1-year comparison.
Learn More
Actively Enrolling
, ,

Alzheimer Prevention Trials (APT) Webstudy

If you are 50 years of age or older, you can monitor your own cognitive health by participating in the Alzheimer Prevention Trials (APT) Webstudy. The APT Webstudy is designed to identify people who may have an increased risk for developing Alzheimer’s disease, using the latest technology to monitor their cognitive performance through regular online memory testing. Volunteers of the APT Webstudy participate at their convenience, anywhere they have access to the internet.
Learn More
Actively Enrolling
, ,

AHEAD Study

AHEAD Study is a global multicenter clinical trial aimed at preventing memory loss due to Alzheimer’s disease, designed and conducted by the Alzheimer’s Clinical Trials Consortium (ACTC) in collaboration with Eisai. Funding is through a public-private partnership with National Institute on Aging (NIH), Eisai, and several philanthropic organizations. It is led by three academic principal investigators: Dr. Paul Aisen from University of Southern California, and Drs. Reisa Sperling and Keith Johnson from Brigham and Women’s Hospital and Massachusetts General Hospital, Harvard Medical School.
Learn More
Actively Enrolling
, ,

Synaptic Therapy Alzheimer’s Research Trial

This study is investigating whether CT1812, a novel and promising therapeutic candidate can halt or slow the process of Alzheimer’s disease. The START Study is a nationwide clinical trial and will enroll approximately 540 individuals. Participants aged 50 to 85 with mild cognitive impairment (MCI) due to Alzheimer’s disease, or mild Alzheimer’s disease who have elevated amyloid in the brain (as measured by PET or CSF), are sought. Participants will be randomized to receive CT1812 or placebo for 18 months. In addition to a battery of cognitive measures, the study will use a variety of biomarkers to evaluate target engagement and assess changes in neurodegeneration and disease progression.
Learn More
Actively Enrolling
, , ,

Alzheimer’s Disease Neuroimaging Initiative (ADNI)

The Alzheimer’s Disease Neuroimaging Initiative (ADNI), a landmark study that began in 2004, is a public-private research partnership tasked with identifying biomarkers to detect Alzheimer’s disease (AD). The study has gathered and analyzed thousands of brain scans, genetic profiles and biomarkers in blood and cerebrospinal fluid (CSF) and was designed to enable researchers to follow AD as it progresses in an individual, from various points in the disease process. The newest iteration of the study, called ADNI4, aims to recruit 750 new participants age 55-90 and bring over 750 rollover participants from ADNI3.
Learn More
Actively Enrolling
, ,

Life’s End Benefits of Cannabidiol and Tetrahydrocannabinol (LiBBY)

Approximately fifty percent of people diagnosed with Alzheimer’s disease or other types of dementia will receive hospice care at the end of their life. Of these, over seventy percent will be prescribed psychiatric medications for management of agitation. Recent research suggests that derivatives of cannabis can be beneficial in controlling agitation and distress without the side effects of medications commonly used to treat agitation. This project aims to test the efficacy of an oral combination of two cannabinoids, tetrahydrocannabinol (THC) and cannabidiol (CBD), for the treatment of agitation in participants with a diagnosis of dementia who are eligible for hospice and experiencing agitation. The study will recruit 150 participants from 15 clinical trial sites in the United States over a 2-year period. To facilitate recruitment and retention and to monitor long-term safety of the THC/CBD combination, completers of the double-blind study will then have the option to participate in a 6-month, open-label extension study.
Learn More